(MENAFN- Baystreet) Cisco Reveals Hypershield
Musk Apologies for“Incorrectly Low” Severance Package
Alaska Airlines Airborne on Q2 Numbers
D.R. Horton Stock Rises 3% On Earnings Beat
These Are the Most Actively-Traded Stocks Previous Articles Subscribe to Get Small Cap News & Alerts Glenn Wilkins - Thursday, April 18, 2024
Callitidas Flat on Data Release
Calliditas Therapeutics AB (NASDAQ: CALT) announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires this week.
"We were pleased to share additional analyses from the two-year Phase 3 NeflgArd trial of Nefecon in IgAN at this year's World Congress of Nephrology," said Chief Medical Officer Richard Philipson. "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."
TARPEYO is contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of TARPEYO. Serious hypersensitivity reactions, including anaphylaxis, have occurred with other budesonide formulations.
According to Thursday morning's news release, atients with moderate to severe hepatic impairment (Child-Pugh Class B and C respectively) could be at an increased risk of hypercorticism and adrenal axis suppression due to an increased systemic exposure to oral budesonide. Avoid use in patients with severe hepatic impairment (Child-Pugh Class C). Monitor for increased signs and/or symptoms of hypercorticism in patients with moderate hepatic impairment (Child-Pugh Class B).
Shares in CALT closed Wednesday at $18.74.
About Us Contact Us Advertise License Our Content Jobs Disclaimer Privacy Policy
Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks
MENAFN18042024000212011056ID1108111284
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.